Biokier
Chapel Hill, US · Founded 2008 · 1 known investors
BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery. The company is a clinical-stage biotech pursuing regulatory approval via the 505(b)2 NDA pathway.
Founders & leadership
JR
Jerzy R SzewczykNamed on SEC filing
RD
Roger D NolanNamed on SEC filing
JF
James FarrellyNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$335K disclosed across 2 rounds · 2011–2014
▶$230KraisedOct 2014 · 7 investors · BiotechnologyRule 506(b)
▶$230KraisedOct 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James FarrellyDirector
- Jerzy R SzewczykExecutive Officer, Director
- Roger NolanExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $230K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$105KraisedMar 2012 · 6 investors · BiotechnologyRule 506(b)
▶$105KraisedMar 2012 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jerzy R SzewczykExecutive Officer, Director
- Roger D NolanExecutive Officer, Director
- James FarrellyDirector
- Offering amount
- $400K
- Amount sold
- $105K
- First sale
- Aug 2011
- Incorporated
- Corporation, Delaware, 2008
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $224.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Biokier do?
- BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery. The company is a clinical-stage biotech pursuing regulatory approval via the 505(b)2 NDA pathway.
- Who are Biokier's investors?
- Biokier's investors include Broadview Ventures.
- How much funding has Biokier raised?
- Biokier has disclosed $335K raised across 2 rounds.
- Where is Biokier headquartered?
- Biokier is headquartered in Chapel Hill, US.